Novel Handheld Device More Than Doubles Success Rates of Valsalva Maneuver in Supraventricular Tachycardia: A Randomized Clinical Trial

Introduction: The Persistent Challenge of SVT Management

Supraventricular tachycardia (SVT) remains a frequent reason for emergency department visits and acute clinical interventions. While often non-life-threatening in stable patients, the rapid heart rates associated with SVT can lead to palpitations, chest discomfort, and significant patient anxiety. Current international guidelines, including those from the American College of Cardiology (ACC) and the European Society of Cardiology (ESC), recommend the Valsalva maneuver (VM) as the first-line, non-pharmacological treatment for stable SVT.

However, the real-world success rate of the standard Valsalva maneuver has historically been underwhelming, often cited between 5% and 20%. Even with the introduction of the modified Valsalva maneuver (involving postural changes), many patients still require intravenous adenosine—a drug known for its distressing side effects, including transient asystole and a sense of impending doom. The primary barrier to VM success is the difficulty patients face in achieving and maintaining the specific intrathoracic pressure (typically 40 mmHg for 15 seconds) required to trigger the necessary vagal response.